Brief introduction of 30459-17-7

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.30459-17-7,1-(4-Trifluoromethylphenyl)piperazine,as a common compound, the synthetic route is as follows.

3-(Trans-4-tert-butoxycarbonylamino-cyclohexyl)-propanoic acid (50 mg, 0.18 mmol) and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (140 mg, 0.37 mmol) were dissolved in a mixture of dimethylacetamide (1.2 mL) and dichloromethane (0.3 mL). Next, diisopropylethylamine (100 muL, 0.55 mmol) was added. After 5 min, a solution of 1-(4-trifluormethyl-phenyl)-piperazine (50 mg, 0.22 mmol) in dimethylacetamide (1.2 mL) and dichloromethane (0.3 mL) was added, and the resulting mixture was stirred at room temperature for 30 min. The mixture was then diluted with dichloromethane (40 mL), and the organic layer was washed with water (2×20 mL), washed with saturated aqueous ammonium chloride (20 mL), washed with water (10 mL), washed with saturated aqueous hydrogencarbonate (2×20 mL), and washed with water (10 mL). The organic phase was dried over magnesium sulfate, filtered, and concentrated under vacuum. The crude product was purified by column chromatography on silica gel (pentane/ethyl acetate, 5:1), and the desired product was isolated as a light yellow solid (68 mg, 76% yield).

30459-17-7, The synthetic route of 30459-17-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; INTERVET INTERNATIONAL B.V.; WO2009/77527; (2009); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics